Health Advocacy, Inc. : how pharmaceutical funding changed the breast cancer movement / Sharon Batt.
By: Batt, Sharon [author.].
Publisher: Vancouver : UBC Press, ©2017Description: xii, 383 pages : illustrations ; 24 cm.Content type: text Media type: unmediated Carrier type: volumeISBN: 9780774833844.Subject(s): Patient advocacy -- Canada | Breast -- Cancer -- Research -- Canada -- Finance | Pharmaceutical industry -- Canada | Medical policy -- Canada | Patient Advocacy -- history | Breast Neoplasms | Drug Industry -- history | Drug Industry -- economics | Pharmaceutical Research -- economics | Health Policy | Patients -- Droits -- Canada | Patients -- Droits -- Canada -- Finances | Sein -- Cancer -- Patients -- Canada | Industrie pharmaceutique -- Canada | Politique sanitaire -- Canada | Breast -- Cancer -- Research -- Finance | Medical policy | Patient advocacy | Pharmaceutical industry | Canada | CanadaGenre/Form: Print books.Current location | Call number | Status | Date due | Barcode | Item holds |
---|---|---|---|---|---|
On Shelf | R727.45 .B38 2017 (Browse shelf) | Available | AU00000000010931 |
Browsing Alfaisal University Shelves , Shelving location: On Shelf Close shelf browser
Includes bibliographical references, Internet addresses, and index.
Canada's health policy landscape -- Health advocacy organizations in Canada -- Beginnings of the breast cancer movement -- Advocacy redefined -- The movement fractures over pharma funding -- Pharma funding as the new norm -- Advocacy groups and the continuing struggle over the pharma-funding question.
"Today, most patient groups in Canada are funded by the pharmaceutical industry, raising an important ethical question: Do alliances between patient organizations and corporate sponsors ultimately lead to policies that are counter to the public interest? In this examination of Canada's breast cancer movement from 1990 to 2010, health activist, scholar, and cancer survivor Sharon Batt investigates the relationship between patient advocacy groups and the pharmaceutical industry--and the hidden implications of pharma funding for health policy. Health Advocacy, Inc. dissects the alliances between the companies that sell pharmaceuticals and the individuals who use them, drawing links between neoliberalism and corporate financing, and the ensuing threat to the public health care system. Batt combines archival analysis, interviews with advocacy and industry representatives, and personal observation to reveal how a reduction in state funding drove patient groups to form partnerships with the private sector. The resulting power imbalance continues to challenge the groups' ability to put patients' interests ahead of those of the industry. Batt's conclusion is unsettling: a once-vibrant movement that encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry. This thorough account of the shift from grassroots advocacy to Big Pharma partnership defines the struggles and stakes of activism in public health today."--